Security
BIO-PATH HLDGS INC COM PAR $0.001 NEW · BPTH
BPTHOTCCommon stockHistorical · closed Oct 23, 2026CIK 1133818Updated Oct 6, 2026
BPTH price & chart
This listing closed Oct 23, 2026. Live provider charts are shown only for current listings.
Current security: BPTH
About the company
We are a clinical and preclinical stage oncology and obesity-focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Our drug delivery and antisense technology, called DNAbilize®, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. We believe this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo, the DNAbilize® delivered antisense drug substances are systemically distributed throughout the body to allow for reduction or elimination of target proteins in blood diseases and solid tumors. Through testing in numerous animal studies and dosing in clinical trials, our DNAbilize® drug candidates have demonstrated an excellent safety profile. DNAbilize® is a registered trademark of the Company.
In the news
No coverage from other publishers is available.
Recent filings
1-SA filing
253G2 filing
Unregistered Sales of Equity Securities · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure · Other Events
Items 3.02, 5.03, 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
15-12G filing
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 690,000Source | 2,965,000Source | 5,021,000Source | 746,000Source | 5,118,000Source | 677,000Source | 2,195,000Source | 1,768,000Source | 3,883,000Source | 3,220,000Source | 15,971,000Source | 26,568,000Source |
| Property, Plant and Equipment, NetUSD | — | 42,000Source | 92,000Source | 9,000Source | 48,000Source | — | 21,000Source | 54,000Source | 23,000Source | 76,000Source | 158,000Source | 225,000Source |
| Current assets: | ||||||||||||
| Assets, CurrentUSD | 663,000Source | 2,899,000Source | 4,802,000Source | 680,000Source | 5,019,000Source | 677,000Source | 2,120,000Source | 1,637,000Source | 3,776,000Source | 3,042,000Source | 15,615,000Source | 26,140,000Source |
| Operating Lease, Right-of-Use AssetUSD | 27,000Source | 24,000Source | 127,000Source | 57,000Source | 51,000Source | — | 54,000Source | 77,000Source | 84,000Source | 102,000Source | 198,000Source | 203,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 8,694,000Source | 3,677,000Source | 2,496,000Source | 7,904,000Source | 3,827,000Source | 9,163,000Source | 4,784,000Source | 4,393,000Source | 3,729,000Source | 2,779,000Source | 1,797,000Source | 1,111,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 9,000Source | 4,000Source | 11,000Source | 8,000Source | 2,000Source | 10,000Source | 8,000Source | 1,000Source | 6,000Source | 1,000Source | 8,000Source | 7,000Source |
| Additional Paid in CapitalUSD | 117,912,000Source | 114,032,000Source | 106,749,000Source | 117,784,000Source | 113,922,000Source | 117,948,000Source | 117,756,000Source | 108,138,000Source | 117,649,000Source | 108,047,000Source | 105,695,000Source | 103,111,000Source |
| Retained Earnings (Accumulated Deficit)USD | -125,926,000Source | -114,748,000Source | -104,235,000Source | -124,950,000Source | -112,633,000Source | -126,445,000Source | -120,353,000Source | -110,764,000Source | -117,501,000Source | -107,607,000Source | -91,529,000Source | -77,661,000Source |
| Stockholders' Equity Attributable to ParentUSD | -8,004,000Source | -712,000Source | 2,525,000Source | -7,158,000Source | 1,291,000Source | -8,486,000Source | -2,589,000Source | -2,625,000Source | 154,000Source | 441,000Source | 14,174,000Source | 25,457,000Source |
| Liabilities and EquityUSD | 690,000Source | 2,965,000Source | 5,021,000Source | 746,000Source | 5,118,000Source | 677,000Source | 2,195,000Source | 1,768,000Source | 3,883,000Source | 3,220,000Source | 15,971,000Source | 26,568,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 8,683,000Source | 3,375,000Source | 1,357,000Source | 7,864,000Source | 3,010,000Source | 9,151,000Source | 4,744,000Source | 3,812,000Source | 3,295,000Source | 1,906,000Source | 1,684,000Source | 958,000Source |
| Operating Lease, Liability, CurrentUSD | 27,000Source | 26,000Source | 116,000Source | 57,000Source | 55,000Source | — | 54,000Source | 82,000Source | 83,000Source | 103,000Source | 108,000Source | 82,000Source |
| Accounts Payable, CurrentUSD | 4,898,000Source | 1,036,000Source | 277,000Source | 3,479,000Source | 766,000Source | 5,158,000Source | 2,438,000Source | 1,746,000Source | 1,274,000Source | 457,000Source | 667,000Source | 106,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 25,000Source | — | — | — | — | 3,000Source | — | 10,000Source | 113,000Source | 153,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,963,000Source | 2,313,000Source | 964,000Source | 3,906,000Source | 2,189,000Source | 3,020,000Source | 1,991,000Source | 1,984,000Source | 1,938,000Source | 1,346,000Source | 909,000Source | 770,000Source |
| Cash and Cash Equivalents, at Carrying Value | —Source | — | — | — | — | — | — | — | — | — | — | — |
| Preferred Stock, Value, Issued | — | —Source | — | —Source | — | —Source | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -2,852,000Source | -3,157,000Source | -9,894,000Source | -16,078,000Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | 5,000Source | 108,000Source | 170,000Source | 566,000Source | 734,000Source | 851,000Source | 821,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | -38,000Source | -1,313,000Source | -1,038,000Source | -10,575,000Source | -11,535,000Source | -15,103,000Source | -9,917,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | -21,000Source | -70,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 21,000Source | 70,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | 50,000Source | 262,000Source | 174,000Source | 10,696,000Source | 2,203,000Source | 1,734,000Source | 20,006,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | 12,000Source | -1,051,000Source | -864,000Source | 121,000Source | -9,332,000Source | -13,390,000Source | 10,019,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 562,000Source | 0Source | 4,006,000Source | 12,000Source | 122,000Source | 188,000Source | 1,173,000Source | 1,052,000Source | 10,384,000Source | 23,774,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | 27,000Source | 100,000Source | — | — | — | — | — | 600,000Source | 700,000Source | 900,000Source | 800,000Source |
| DepreciationUSD | — | — | — | — | — | — | 2,000Source | 22,000Source | 53,000Source | 82,000Source | 88,000Source | 76,000Source |
| General and Administrative ExpenseUSD | — | 213,000Source | 1,317,000Source | 514,000Source | 1,165,000Source | 259,000Source | 1,264,000Source | 1,407,000Source | 4,697,000Source | 4,235,000Source | 4,736,000Source | 4,533,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 4,000Source | — | 6,000Source | — | — | — | 14,000Source | 36,000Source | 33,000Source | 3,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | -976,000Source | -2,115,000Source | -4,597,000Source | -1,869,000Source | -270,000Source | -2,852,000Source | -3,157,000Source | -9,894,000Source | -16,078,000Source | -13,868,000Source | -10,440,000Source |
| Nonoperating Income (Expense)USD | — | -488,000Source | 519,000Source | -35,000Source | 1,169,000Source | 27,000Source | 389,000Source | 538,000Source | 2,098,000Source | -235,000Source | 33,000Source | 3,000Source |
| Operating ExpensesUSD | — | 488,000Source | 2,634,000Source | 4,562,000Source | 3,038,000Source | 297,000Source | 3,241,000Source | 3,695,000Source | 11,992,000Source | 15,843,000Source | 13,901,000Source | 10,443,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 174,000Source | 10,696,000Source | 1,677,000Source | 1,734,000Source | 15,849,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | — | 4,157,000Source |
| Amortization of Deferred Charges | — | — | — | — | — | —Source | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | -488,000Source | -2,634,000Source | -4,562,000Source | -3,038,000Source | -297,000Source | -3,241,000Source | -3,695,000Source | -11,992,000Source | -15,843,000Source | -13,901,000Source | -10,443,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -9,894,000Source | -16,078,000Source | -13,868,000Source | -10,440,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | -976,000Source | -2,115,000Source | -4,597,000Source | -1,869,000Source | -270,000Source | -2,852,000Source | -3,157,000Source | -9,894,000Source | -16,078,000Source | -13,868,000Source | -10,440,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.7Source | -0.55Source | -1.16Source | — | -0.4Source | -4.88Source | -4.12Source | -33.63Source | -1.91Source | -1.55Source |
| Earnings Per Share, DilutedUSD per share | — | -0.11Source | -0.7Source | -0.55Source | -1.16Source | -0.03Source | -0.4Source | -4.88Source | -4.12Source | -33.63Source | -1.91Source | -1.55Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 3,017,000Source | 8,308,000Source | 1,612,000Source | — | 7,062,000Source | 647,000Source | 2,401,000Source | 478,000Source | 7,276,000Source | 6,725,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | 8,521,000Source | 3,017,000Source | 8,308,000Source | 1,612,000Source | 9,342,000Source | 7,062,000Source | 647,000Source | 2,401,000Source | 478,000Source | 7,276,000Source | 6,725,000Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | 213,000Source | 1,317,000Source | 514,000Source | 1,165,000Source | 259,000Source | 1,264,000Source | 1,407,000Source | 4,697,000Source | 4,235,000Source | 4,736,000Source | 4,533,000Source |
| Investment Income, InterestUSD | — | — | 4,000Source | — | 6,000Source | — | — | — | 14,000Source | 36,000Source | 33,000Source | 3,000Source |
| Nonoperating Income (Expense)USD | — | -488,000Source | 519,000Source | -35,000Source | 1,169,000Source | 27,000Source | 389,000Source | 538,000Source | 2,098,000Source | -235,000Source | 33,000Source | 3,000Source |
| Operating ExpensesUSD | — | 488,000Source | 2,634,000Source | 4,562,000Source | 3,038,000Source | 297,000Source | 3,241,000Source | 3,695,000Source | 11,992,000Source | 15,843,000Source | 13,901,000Source | 10,443,000Source |
| Research and Development ExpenseUSD | — | 275,000Source | 1,317,000Source | 4,048,000Source | 1,873,000Source | 38,000Source | 1,977,000Source | 2,288,000Source | 7,295,000Source | 11,608,000Source | 9,165,000Source | 5,910,000Source |
| Interest Expense, Debt | — | — | — | —Source | — | — | —Source | — | — | — | — | — |
Offerings
Registration 333-284363
Filing attachments
bpth-20250501xex99d1.htm · 8-K · 2025-05-02
EX-99.1 2 bpth-20250501xex99d1.htm EX-99.1 Exhibit 99.1 Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells HOUSTON - May 1, 2025 - Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid …
Read attachment ↗tm2513536d1_ex4-1.htm · 8-K · 2025-04-29
EX-4.1 2 tm2513536d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT …
Read attachment ↗bpth-20250328xex99d1.htm · 8-K · 2025-03-28
EX-99.1 2 bpth-20250328xex99d1.htm EX-99.1 Exhibit 99.1 Bio-Path Holdings Reports Full Year 2024 Financial Results Reports Continued Progress Across Both Obesity and Oncology Franchises HOUSTON - March 28, 2025 - Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its financial results for the year ended December …
Read attachment ↗tm2510724d1_ex4-1.htm · 8-K · 2025-03-28
EX-4.1 2 tm2510724d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT …
Read attachment ↗bpth-20250318xex99d1.htm · 8-K · 2025-03-19
EX-99.1 2 bpth-20250318xex99d1.htm EX-99.1 Exhibit 99.1 Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell Models HOUSTON - March 18, 2025 - Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its pr…
Read attachment ↗tm258626d1_ex4-1.htm · 8-K · 2025-03-07
EX-4.1 2 tm258626d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT O…
Read attachment ↗